Rin Nakamura

1.1k total citations
10 papers, 139 citations indexed

About

Rin Nakamura is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Rin Nakamura has authored 10 papers receiving a total of 139 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Hematology and 4 papers in Immunology. Recurrent topics in Rin Nakamura's work include Multiple Myeloma Research and Treatments (5 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Peptidase Inhibition and Analysis (2 papers). Rin Nakamura is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Peptidase Inhibition and Analysis (2 papers). Rin Nakamura collaborates with scholars based in Australia, United States and Spain. Rin Nakamura's co-authors include Teiko Sumiyoshi, Priti S. Hegde, Grant R. Goodman, Suzanne Trudel, Andrew Spencer, Yukiya Hakozaki, Tetsuo Kirimoto, Paula Rodríguez‐Otero, Voleak Choeurng and Taro Matsuo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Rin Nakamura

10 papers receiving 137 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rin Nakamura Australia	7	95	55	37	31	26	10	139
Holly Lee Canada	9	94 1.0×	100 1.8×	99 2.7×	35 1.1×	24 0.9×	37	187
Ana Alcaraz‐Serna Spain	4	30 0.3×	12 0.2×	45 1.2×	11 0.4×	41 1.6×	5	106
Shalin Kothari United States	6	34 0.4×	18 0.3×	25 0.7×	9 0.3×	22 0.8×	23	104
Wajeeha Aiman United States	6	31 0.3×	54 1.0×	29 0.8×	8 0.3×	7 0.3×	34	132
Valentín Cabañas Spain	6	41 0.4×	66 1.2×	51 1.4×	7 0.2×	4 0.2×	11	106
John Meekin United States	5	139 1.5×	11 0.2×	37 1.0×	87 2.8×	21 0.8×	7	178
Marco Schupp United States	8	96 1.0×	13 0.2×	46 1.2×	4 0.1×	13 0.5×	17	175
Yazeed Sawalha United States	8	97 1.0×	26 0.5×	24 0.6×	19 0.6×	15 0.6×	43	169
Kobby Asubonteng United States	6	64 0.7×	15 0.3×	37 1.0×	5 0.2×	15 0.6×	11	131
Jorge Monge United States	7	46 0.5×	72 1.3×	68 1.8×	7 0.2×	14 0.5×	15	119

Countries citing papers authored by Rin Nakamura

Since Specialization

Citations

This map shows the geographic impact of Rin Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rin Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rin Nakamura more than expected).

Fields of papers citing papers by Rin Nakamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rin Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rin Nakamura. The network helps show where Rin Nakamura may publish in the future.

Co-authorship network of co-authors of Rin Nakamura

This figure shows the co-authorship network connecting the top 25 collaborators of Rin Nakamura. A scholar is included among the top collaborators of Rin Nakamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rin Nakamura. Rin Nakamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Richter, Joshua, Sheeba K. Thomas, Jacob P. Laubach, et al.. (2024). Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies. Blood. 144(Supplement 1). 1021–1021. 8 indexed citations

2.

Mateos, María‐Victoria, Nizar J. Bahlis, Andrew Spencer, et al.. (2023). P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB. HemaSphere. 7(S3). e75458a8–e75458a8. 4 indexed citations

3.

Kumar, Shaji, Carlos Bachier, Michèle Cavo, et al.. (2023). CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.. Journal of Clinical Oncology. 41(16_suppl). TPS8064–TPS8064. 26 indexed citations

4.

Trudel, Suzanne, Nizar J. Bahlis, Andrew Spencer, et al.. (2022). Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity. Blood. 140(Supplement 1). 1363–1365. 27 indexed citations

5.

Nakamura, Rin, Hartmut Koeppen, Anjali Vaze, et al.. (2020). Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 14–15. 10 indexed citations

6.

Li, Yijin, Bharathi Vennapusa, Ching‐Wei Chang, et al.. (2020). Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. Applied immunohistochemistry & molecular morphology. 29(4). 258–264. 27 indexed citations

7.

Sun, Guanghao, Masakazu Okada, Rin Nakamura, et al.. (2018). Twenty‐four‐hour continuous and remote monitoring of respiratory rate using a medical radar system for the early detection of pneumonia in symptomatic elderly bedridden hospitalized patients. Clinical Case Reports. 7(1). 83–86. 18 indexed citations

8.

Yadav, Mahesh, Cherie Green, Rin Nakamura, et al.. (2016). Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma. Blood. 128(22). 2102–2102. 14 indexed citations

9.

Xiao, Yuanyuan, Christina Rabe, Marcin Kowanetz, et al.. (2014). Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC). 5. 1 indexed citations

10.

Xiao, Yuanyuan, Christina Rabe, Marcin Kowanetz, et al.. (2014). Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer. 2(S3). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact